The research comes as popularity of weight loss medications has intensified in recent years, prompting concern about the loss of muscle mass among some GLP-1 users.  

Indeterminate reports can leave ordering providers with unanswered questions that could potentially delay care, authors of a new paper caution. 

Scaling the solution across the U.S. has the potential to mitigate the current shortfall of breast radiologists, researchers contend. 

First introduced a year ago, the Patients Deserve Price Tags Act would require hospitals to post the cost for 300 “shoppable” services across radiology and other specialties. 

Similar to BI-RADS, the system is intended to standardize terminology, describe specific findings, improve communication and guide patient care.  

A notice from the agency indicates that systems that have had column replacements might not function appropriately afterward and could pose patient harm.

Addressing these gaps will require more inclusive risk prediction models and system-level interventions such as EMR optimization and provider education to improve uptake. 

“Today’s decision affirms that speaking honestly to our elected representatives is not misconduct—it is a constitutional right," Wyoming radiologist Eric Cubin, MD, said. 

In theory, GLP-1 receptor agonist drugs like semaglutide and tirzepatide should save a lot of money for the health insurers that pay for them. As it turns out, the lived reality is not keeping pace with the idealistic expectation. 

Ami B. Bhatt, MD, a veteran cardiologist and digital health specialist, stepped down as the American College of Cardiology's chief innovation officer to accept this new role.